Fatahinia Mahnaz, Halvaeizadeh Marzieh, Zarei Mahmoudabadi Ali, AboualiGalehdari Elham, Kiasat Neda
Infectious and Tropical Diseases Research Center, Health Research Institute, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.
Department of Medical Mycology, School of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.
Curr Med Mycol. 2020 Jun;6(2):1-6. doi: 10.18502/CMM.6.2.2692.
is the second cause of candidiasis. The mortality rate of infections is about 40%; accordingly, it may be life threatening, especially in immunocompromised hosts. Regarding this, the current study was conducted to evaluate the regional patterns of the antifungal susceptibility of clinical isolated from the patients referring to the health centers located in Ahvaz, Iran.
In this study, a total of 30 clinical strains of isolates were recovered from different body sites (i.e., vagina, mouth, and urine). Phenotypic characteristics and molecular methods were used to identify the isolates. The minimum inhibitory concentration (MIC) was determined according to the European Committee on Antimicrobial Susceptibility Testing.
Our findings demonstrated that 20%, 80%, and 6.7% of the isolates were resistant to amphotericin B, terbinafine, and posaconazole, respectively, while all the isolates were found to be fluconazole susceptible dose dependent and susceptible to voriconazole and caspofungin.
Our study suggested that voriconazole had high potency against isolates. Consequently, this antifungal agent can be an alternative drug in the treatment of resistant patients. These results can be helpful for the successful treatment of patients in different regions.
是念珠菌病的第二大病因。感染的死亡率约为40%;因此,它可能危及生命,尤其是在免疫功能低下的宿主中。鉴于此,本研究旨在评估从转诊至伊朗阿瓦士卫生中心的患者中临床分离的念珠菌的抗真菌药敏区域模式。
在本研究中,共从不同身体部位(即阴道、口腔和尿液)分离出30株念珠菌临床菌株。采用表型特征和分子方法鉴定分离株。根据欧洲抗菌药物敏感性试验委员会的标准测定最低抑菌浓度(MIC)。
我们的研究结果表明,分别有20%、80%和6.7%的分离株对两性霉素B、特比萘芬和泊沙康唑耐药,而所有分离株对氟康唑敏感,且对伏立康唑和卡泊芬净敏感。
我们的研究表明伏立康唑对念珠菌分离株有高效力。因此,这种抗真菌药物可作为耐药患者治疗的替代药物。这些结果有助于不同地区患者的成功治疗。